Lambert-Eaton肌无力综合征患者的长期随访、生活质量与生存
这项观察性研究纳入150例Lambert-Eaton肌无力综合征(LEMS)患者,比较非肿瘤(NT)与small cell lung cancer(SCLC)亚型的生存,并评估功能与健康相关生活质量(HRQOL)。NT-LEMS生存与荷兰一般人群相似;SCLC-LEMS肿瘤生存较非LEMS的SCLC患者延长(中位17 vs 7.0个月,p<0.0001)。多数LEMS患者病程稳定,治疗后日常生活独立比例由62%升至1年85%。
要点
- NT-LEMS患者生存与一般人群相似。
- SCLC-LEMS肿瘤生存优于非LEMS的SCLC患者。
- 多数患者病程稳定,1年时85%日常生活独立。
核心结论
- NT-LEMS患者生存正常,SCLC-LEMS患者肿瘤生存改善,且多数LEMS患者病程稳定并保持或恢复自理独立。
研究设计与样本
- 观察性研究,纳入150例LEMS患者,其中65例NT-LEMS、81例SCLC-LEMS。
- 生存分别与荷兰一般人群及非LEMS的SCLC患者比较,并回顾性记录病程。
- 采用多个量表评估功能损害与健康相关生活质量(HRQOL)。
主要发现
- 65例NT-LEMS生存与荷兰一般人群相似。
- 81例SCLC-LEMS较非LEMS的SCLC患者肿瘤生存显著更长(总体中位生存17 vs 7.0个月,p<0.0001)。
- 63例有完整随访数据者中,诊断时39例(62%)日常生活独立,1年随访升至85%。
- LEMS患者躯体HRQOL综合评分55.9,显著低于一般人群76.3(p<0.0001),与myasthenia gravis患者60.5相当。
- LEMS患者心理HRQOL综合评分71.8,与一般人群77.9(p=0.19)及myasthenia gravis患者70.3相当。
临床怎么用
- 对NT-LEMS患者可预期生存与一般人群相近。
- SCLC-LEMS患者肿瘤生存可能优于非LEMS的SCLC患者,即使校正肿瘤分期后仍改善。
- 治疗后可改善日常生活独立性,1年时多数患者可自理。
- 应关注LEMS患者躯体HRQOL受损,其程度与myasthenia gravis患者相当。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study survival and to characterize long-term functional impairments and health-related quality of life (HRQOL) of patients with Lambert-Eaton myasthenic syndrome (LEMS). METHODS: In this observational study, survival of patients with LEMS, separately for nontumor (NT) and small cell lung cancer (SCLC), was compared to that of the Dutch general population and patients with SCLC. Disease course in patients with LEMS was recorded retrospectively. Several scales for functional impairments and health-related quality of life were assessed. RESULTS: We included 150 patients with LEMS. Survival was similar to that of the general population in 65 patients with NT-LEMS. Tumor survival was significantly longer in 81 patients with SCLC-LEMS compared to patients with non-LEMS SCLC (overall median survival 17 vs 7.0 months, p < 0.0001). At diagnosis, 39 (62%) of 63 patients with complete follow-up data were independent for activities of daily living, improving to 85% at the 1-year follow-up. The physical HRQOL composite score (55.9) was significantly lower than in the general population (76.3, p < 0.0001) and comparable to that of patients with myasthenia gravis (60.5). The mental HRQOL composite score was 71.8 in patients with LEMS, comparable to that of the general population (77.9, p = 0.19) and patients with myasthenia gravis (70.3). CONCLUSIONS: This study shows that patients with NT-LEMS have normal survival. Patients with SCLC-LEMS have an improved tumor survival, even after correction for tumor stage. A majority of patients with LEMS report a stable disease course and remain or become independent for self-care after treatment.
引用
- Lipka AF, Boldingh MI, van Zwet EW, et al. Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome. Neurology. 2019. PMID: 31831596. doi:10.1212/WNL.0000000000008747
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。